A COMPARATIVE IMMUNOHISTOCHEMICAL STUDY OF MALIGNANT MESOTHELIOMA ANDRENAL-CELL CARCINOMA - THE DIAGNOSTIC UTILITY OF LEU-M1, BER EP4, TAMM-HORSFALL PROTEIN AND THROMBOMODULIN
Rl. Attanoos et al., A COMPARATIVE IMMUNOHISTOCHEMICAL STUDY OF MALIGNANT MESOTHELIOMA ANDRENAL-CELL CARCINOMA - THE DIAGNOSTIC UTILITY OF LEU-M1, BER EP4, TAMM-HORSFALL PROTEIN AND THROMBOMODULIN, Histopathology, 27(4), 1995, pp. 361-366
Metastatic renal cell carcinoma has occasionally been reported to mimi
c malignant pleural mesothelioma. Morphologically, histochemically and
immunohistochemically, similarities in the two tumours exist making t
heir differentiation difficult, particularly in biopsy specimens. The
aim of this study was to make a comparative immunohistochemical analys
is of the two tumours by use of a panel of four antibodies (Leu M1; Be
r EP4; thrombomodulin and Tamm-Horsfall protein). Their suitability in
differentiating between the two tumours was assessed. We examined 20
cases of renal cell carcinoma and 20 cases of malignant pleural mesoth
elioma. On immunostaining with Leu M1, 14 of 20 renal cell carcinomas
were positive, yielding 70% sensitivity and 95% specificity and one of
20 mesotheliomas. In comparison, Ber EP4 antibody stained only seven
of 20 of the renal cell carcinomas. In addition, it was noted that fou
r tubulopapillary pattern renal cell carcinomas stained positively wit
h both anti-Leu M1 antibody and Ber EP4 antibody. Thrombomodulin immun
ostaining was present in 11 of 20 mesotheliomas (55% sensitivity and d
emonstrated 95% specificity) and one of 20 renal cell carcinomas. For
epithelial mesotheliomas only, thrombomodulin staining was identified
in 10 of 14 cases. In the differentiation of renal cell carcinoma from
epithelial mesothelioma we recommend the use of Leu M1 and thrombomod
ulin as diagnostically useful markers. None of the antibodies used in
this study was effective in distinguishing sarcomatoid renal cell carc
inoma from sarcomatous mesothelioma. Tamm-Horsfall protein showed litt
le diagnostic utility in differentiating the two tumours.